These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32837113)

  • 61. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Identifying the natural compound Catechin from tropical mangrove plants as a potential lead candidate against 3CL
    Jha RK; Khan RJ; Parthiban A; Singh E; Jain M; Amera GM; Singh RP; Ramachandran P; Ramachandran R; Sachithanandam V; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022; 40(24):13392-13411. PubMed ID: 34644249
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Disulfiram inhibits coronaviral main protease by conjugating to its substrate entry site.
    Kuan Y; Chu HF; Hsu PH; Hsu KC; Lin TH; Huang CH; Chen WY
    Int J Biol Macromol; 2024 Sep; 276(Pt 2):133955. PubMed ID: 39025177
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study.
    Mondal M; Sarkar C; Jamaddar S; Khalipha ABR; Islam MT; Mahafzah A; Mubarak MS
    Infect Disord Drug Targets; 2021; 21(7):e160921188777. PubMed ID: 33292147
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Structural basis of SARS-CoV-2 3CL
    Tahir Ul Qamar M; Alqahtani SM; Alamri MA; Chen LL
    J Pharm Anal; 2020 Aug; 10(4):313-319. PubMed ID: 32296570
    [TBL] [Abstract][Full Text] [Related]  

  • 66. SARS-CoV-2 replication and drug discovery.
    Nazir F; John Kombe Kombe A; Khalid Z; Bibi S; Zhang H; Wu S; Jin T
    Mol Cell Probes; 2024 Oct; 77():101973. PubMed ID: 39025272
    [TBL] [Abstract][Full Text] [Related]  

  • 67. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 68. SARS-CoV-2 M
    Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
    J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL
    Alamri MA; Tahir Ul Qamar M; Mirza MU; Bhadane R; Alqahtani SM; Muneer I; Froeyen M; Salo-Ahen OMH
    J Biomol Struct Dyn; 2021 Aug; 39(13):4936-4948. PubMed ID: 32579061
    [TBL] [Abstract][Full Text] [Related]  

  • 70. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.
    Gul S; Ozcan O; Asar S; Okyar A; Barıs I; Kavakli IH
    J Biomol Struct Dyn; 2021 Oct; 39(17):6772-6791. PubMed ID: 32752938
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery.
    Wang Z; Yang L; Zhao XE
    Comput Struct Biotechnol J; 2021; 19():4684-4701. PubMed ID: 34426762
    [TBL] [Abstract][Full Text] [Related]  

  • 73. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Picornaviral 3C protease inhibitors and the dual 3C protease/coronaviral 3C-like protease inhibitors.
    Wang HM; Liang PH
    Expert Opin Ther Pat; 2010 Jan; 20(1):59-71. PubMed ID: 20021285
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2.
    Tripathi PK; Upadhyay S; Singh M; Raghavendhar S; Bhardwaj M; Sharma P; Patel AK
    Int J Biol Macromol; 2020 Dec; 164():2622-2631. PubMed ID: 32853604
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
    Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Exploring epigenetic drugs as potential inhibitors of SARS-CoV-2 main protease: a docking and MD simulation study.
    Uzuner U; Akkus E; Kocak A; Çelik Uzuner S
    J Biomol Struct Dyn; 2024 Aug; 42(13):6892-6903. PubMed ID: 37458994
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Plant Products as Inhibitors of Coronavirus 3CL Protease.
    Mandal A; Jha AK; Hazra B
    Front Pharmacol; 2021; 12():583387. PubMed ID: 33767619
    [No Abstract]   [Full Text] [Related]  

  • 79. An
    Mishra B; Ballaney P; Saha G; Shinde A; Banerjee S; Thimmakondu VS; Aduri R
    J Biomol Struct Dyn; 2023 May; 41(8):3167-3186. PubMed ID: 35261325
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Khare P; Sahu U; Pandey SC; Samant M
    Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.